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Abstract
Objective—To describe outcomes of HIV-infected pediatric patients with drug-resistant 
tuberculosis (DR TB).
Methods—Demographic, clinical, and laboratory data from pediatric patient charts treated for 
DR TB during 2005–2008 were collected retrospectively from five MDR TB hospitals in South 
Africa. Data were summarized and Pearson’s chi-squared test or Fisher’s exact test were used to 
assess differences in variables of interest by HIV status. A time-to-event analysis was conducted 
using days from start of treatment to death. Variables of interest were first assessed using the 
Kaplan-Meier method. Cox proportional hazard models were fit to estimate crude and adjusted 
hazard ratios.
Results—Of 423 eligible participants, 398 (95%) had culture-confirmed DR-TB and 238 (56%) 
were HIV-infected. A total of 54% were underweight, 42% were male and median age was 10.7 
years (IQR: 5.5–15.3). Of the 423 participants, 245 (58%) were successfully treated, 69 (16%) 
died, treatment failed in 3 (1%), 36 (9%) were lost to follow-up, and 70 (17%) were still on 
treatment, transferred or had unknown outcomes. Time to death differed by HIV status (p=0.008), 
sex (p<0.001), year of TB diagnosis (p=0.05) and weight status (p=0.002). Over the two-year risk 
period, the adjusted rate of death was 2-fold higher among participants with HIV compared to 
HIV-negative participants (aHR=2.28; 95% CI: 1.11, 4.68).
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Conclusions—Male, underweight, and HIV-infected children with DR TB were more likely to 
experience death when compared to other children with DR TB within this study population.
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Introduction
In 2015 there were an estimated 480,000 new cases of multidrug-resistant tuberculosis 
(MDR TB), defined as TB having resistance to at least isoniazid (INH) and rifampicin (RIF) 
(1, 2). An estimated one million children develop TB each year (1). Pediatric TB results 
from recent transmission (as opposed to reactivation), especially in young children (3–7). 
Attempts to quantify the incidence of MDR TB in children estimate that 3.2% of new 
pediatric TB cases are MDR TB and indicate that the risk of MDR TB is generally similar 
among children and adults (3, 8). As expected, estimates of drug resistance in children are 
often higher in high-burden countries. In South Africa, it is estimated that 15% of pediatric 
patients with culture-confirmed TB have a strain resistant to INH and 8.9% have MDR TB, 
similar to adults (1, 7, 9–11).
Approximately 12% of the 9.6 million incident cases of TB around the world in 2014 were 
also infected with human immunodeficiency virus (HIV) (1). South Africa has one of the 
highest burdens of HIV-infected TB cases worldwide. In 2014, 61% of incident TB cases in 
South Africa were also infected with HIV (1). HIV-infected TB cases present additional 
challenges in treating DR TB and are associated with worse treatment outcomes and survival 
(12–16). In South Africa, data from a variety of cross sectional studies indicate that 11%–
64% of children with TB are HIV-infected (17). Although there is conflicting evidence about 
the association between HIV infection and drug-resistant TB (7, 18, 19), once infected with 
TB, children who are younger or HIV-infected are more likely to progress to TB disease 
(20). In South Africa, each adult with MDR TB has, on average, nearly two contacts who are 
younger than five years (4).
Outcomes and survival in adults co-infected with TB and HIV can be improved with 
simultaneous treatment of both diseases (21–23), but few studies (small cohort studies and 
case series) describe treatment outcomes of co-infected pediatric patients (10, 24–27). 
Previous studies have demonstrated that mortality among children with DR TB in South 
Africa differs by province (12%–31%), but overall treatment success rates (70%–83%) can 
be similar to, if not better than, those seen in adults (28–30). The objective of this analysis 
was to assess the association between treatment outcomes with HIV status and other risk 
factors among children and adolescents with MDR TB.
Methods
Ethics
Ethics approval for this project was obtained from the South African National Department of 
Health (NDOH), each provincial Department of Health, the City of Johannesburg and all 
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participating hospitals. Institutional Review Board approval was obtained from the South 
African Medical Research Council Ethics Committee and the Human Research Ethics 
Committee of University of the Witwatersrand in Johannesburg. This project was reviewed 
by the Centers for Disease Control and Prevention, Atlanta, GA, USA and determined to be 
routine disease surveillance.
Data Collection
The setting and data collection process for this analysis have been previously described (29). 
Briefly, this was a retrospective cohort study of abstracted data from the records of all 
children (<13 years) and adolescents (13–17 years) diagnosed with DR TB between January 
1, 2005, and June 30, 2010, at five MDR TB hospitals located in Eastern Cape, Gauteng, 
Kwazulu-Natal and Limpopo provinces. Eligibility criteria included patients younger than 
18 years of age with laboratory-confirmed DR TB, and/or treatment for drug-resistant TB 
during the study period. Demographic, clinical, and laboratory data were abstracted from 
medical records using a standardized form. When patient records at the MDR TB hospitals 
were incomplete, data were abstracted from alternate sources including TB surveillance 
systems, hospital databases, the National Health Laboratory Service (NHLS) database and 
patient charts from referring facilities.
Definitions
We used standard anti-TB drug resistance category definitions for INH and RIF mono-
resistance, poly-resistance, MDR, and extensive drug resistance (XDR) (31). Pre-extensively 
drug-resistant TB (Pre XDR TB) was defined as MDR TB plus resistance to any 
fluoroquinolone or second-line injectable drug (capreomycin, kanamycin or amikacin), but 
not both.
A DR TB treatment regimen was defined as any TB treatment regimen that differed from 
standard first-line therapy and was started after registration at a MDR TB hospital. WHO 
recommends that MDR TB treatment regimens include at least four effective second-line 
anti-TB drugs, including a fluoroquinolone and second-line injectable drug (32). For the 
time period during which this cohort was diagnosed and treated, there were no standard 
national guidelines for treatment of drug-resistant TB in children in South Africa.
Weight-for-age z-scores were calculated as a marker of malnutrition. Underweight was 
defined according to WHO definition, as below two standard deviations below the mean. 
Severely underweight was defined as below three standard deviations below the mean. 
Standard WHO definitions for MDR TB treatment outcome were used: cure/complete, died, 
failed, lost to follow up, unknown/on treatment /transfer (33). Death was the outcome of 
interest for the survival analysis.
Statistical Methods
Data were analyzed using SAS 9.4 (SAS Institute, Cary, North Carolina, USA). This 
analysis was limited to participants diagnosed before 2009 (to allow time to ascertain 
treatment outcome) with a documented HIV status and treatment outcome. Observations 
from Limpopo province were excluded because of the small number of participants (n=5) 
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from that province that were diagnosed before 2009. The very small number of participants 
with isoniazid mono-resistance or poly-resistance were excluded from the analysis of 
outcomes in order to satisfy convergence criteria. Participants with mono-resistance to 
rifampicin were included with the MDR participants. Frequencies and proportions were 
reported for all categorical variables. Pearson’s chi-squared test, Fisher’s exact test or 
Wilcoxon-Mann-Whitney tests were used to assess bivariate associations of categorical 
variables of interest with HIV status. An alpha of 0.05 was used to test the statistical 
significance of all associations.
To assess the effect of HIV infection on the rate of poor outcomes, a time-to-event analysis 
was conducted. The event of interest was death. Participants contributed person-time from 
the start of DR TB treatment (T0) until the date of event or the date they were censored (T1). 
Participants who were cured, completed treatment or failed treatment were censored on the 
date they reached their treatment outcome. Participants who were still on treatment, 
transferred or were lost to follow up were censored on the last date of contact. Participants 
who had not experienced the event of interest after 2 years of follow-up were censored at 
730.5 days. Those who were not on treatment for at least 15 days (T1−T0 < 15) were 
excluded from the survival analysis.
Variables of interest (HIV status, sex, age, province, year of TB diagnosis, resistance profile, 
presence of extra pulmonary TB and weight status) were first assessed independently using 
the Kaplan-Meier method and log-rank tests. In order to calculate hazard ratios and 
corresponding confidence intervals as a measure of effect, statistically significant variables 
(and variables that are known to influence survival) were considered for inclusion in 
bivariate and multivariable Cox proportional hazard models.
The proportional hazard assumption was assessed visually win unadjusted –ln-ln curves and 
tested statistically by looking at the significance of time dependent covariates and goodness 
of fit methods that assess the correlation between Schoenfeld residuals and ranked failure 
times. In order to satisfy the proportional hazards assumption for the time to event analysis, 
age was collapsed into a dichotomous variable indicating 0–7 years old and 8–17 years old. 
PreXDR TB and XDR TB were also collapsed to create a dichotomized variable that 
indicated PreXDR/XDR TB versus MDR TB. Cox proportional hazard bivariate models 
were fit with each individual predictor that did not violate the proportional hazards 
assumption. Variables that were significant in the bivariate models were then included in the 
multivariable analysis. A Cox proportional hazards model, stratified on province and year of 
diagnosis, was fit to determine adjusted hazard ratios (aHR).
Results
Demographic and Clinical Information
There were 774 eligible children and adolescents diagnosed with DR TB at MDR-TB 
hospitals in the four areas. A total of 423 were eligible for this analysis and slightly more 
than half (n=238, 56%) were HIV-infected (Table 1). Culture results were available for 419 
(99.1%) participants, 398 (95.0%) of which were positive. The majority of participants were 
cared for in KwaZulu-Natal (n=252, 59.6%), had a median age of 10.7 years (IQR: 5.5–
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15.3) and less than half were male (n=177, 41.9%). Age differed by HIV status (p<0.001), 
with HIV-negative participants tending to be older than HIV-infected patients. More HIV-
infected participants were male (47.7%) than HIV negative participants (34.6%, p=0.007). A 
significantly higher proportion of HIV-infected participants were severely underweight 
compared to those who were HIV-negative (n=86, 38.7% vs. n=30, 17.1%, p<0.001).
Among participants with data on previous TB treatment history (n=341), HIV-infected 
individuals were more likely to have been previously treated (58.7%) than HIV negative 
participants (36.4%, p<0.001). Among participants who had information about their contact 
history (n=249), previous contact with an MDR/XDR TB case was higher among HIV 
negative individuals, but this difference did not reach statistical significance (p=0.08). There 
was no significant difference in the number of symptoms reported by HIV status (p=0.6).
HIV-negative participants were more likely to have had a positive smear microscopy test 
(68.2%) compared to HIV-infected participants (59.2%), but this did not reach statistical 
significance (p=0.06). There were 389 (92.0%) participants that had at least one chest 
radiograph and 378 (97.2%) were reported as abnormal. HIV infected individuals were more 
likely to have extrapulmonary TB (32.9%) compared to individuals without HIV (9.1%, 
p<0.001). There were 391 (92.4%) participants that had at least one drug susceptibility test 
recorded. There was not a statistically significant difference in the distribution of resistance 
profiles by HIV status (p=0.07).
Of the 238 HIV-infected participants, only 133 (55.9%) had at least one documented CD4 
count, of which 52 (39.1%) had at least one CD4 count below 200. There were 162 (68.1%) 
HIV-infected participants who had a record of Highly Active Antiretroviral Therapy 
(HAART) before or during the current TB episode and 142 (60.0%) that had record of Co-
trimoxazole preventive therapy (CPT).
There were 245 (57.9%) participants successfully treated (cure/complete), 69 (16.3%) died, 
3 (0.7%) treatment failed, 36 (8.5%) were lost to follow-up, and 70 (16.6%) were still on 
treatment, transferred or unknown. A significantly higher proportion of HIV negative 
participants were cured or completed treatment than participants who were HIV-positive 
(61.6% vs. 55.0%; p=0.02). A higher proportion of HIV-infected participants (20.6% vs. 
10.8% of HIV negative) died while on treatment.
Rate of Poor Treatment Outcomes
The Kaplan-Meier estimator indicated that time to death was significantly different by HIV 
status (p=0.008), sex (p<0.001), province (p=0.045) and weight status (p=0.002) (Table 2). 
Year of TB diagnosis (p=0.054) and age (p=0.09) were close to being statistically different. 
Over the two-year risk period, HIV-infected participants experienced an unadjusted hazard 
of death that was more than 2-fold higher than participants who were HIV-negative 
(HR=2.20, 95%CI: 1.22, 3.97) (Table 3) (Figure 1). The multivariable Cox proportional 
hazard model was stratified on province and year of diagnosis and contained covariates for 
HIV status, sex, age and weight. There were 372 observations that contributed person-time 
to this risk set. Of those, 50 (13.4%) participants experienced death and 322 (86.6%) were 
censored. Over the two-year risk period, the adjusted rate of death was over 2-fold higher 
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among participants with HIV compared to participants who were HIV-negative (aHR=2.28, 
95%CI: 1.11, 4.68). Males (aHR=2.69, 95%CI: 1.47, 4.9) and participants that were 
underweight (aHR=2.65, 95%CI: 1.37, 5.13) also experienced significantly higher hazards 
of death.
Discussion
This analysis of pediatric patients with DR TB describes the clinical presentation and 
treatment outcomes of those diagnosed in three of the eastern provinces of South Africa. 
These results indicate that favorable outcomes are achievable in pediatric MDR TB patients, 
with 57.9% of the participants in our cohort experiencing cure or treatment completion 
outcome. However, the rate of death was higher among children who were HIV positive, 
male or underweight. The treatment success rate in our cohort of children with DR TB was 
higher than the global treatment success rate for all MDR TB cases, but lower than other 
published cohorts of pediatric MDR TB (refs: WHO global TB report 2015, hicks, seddon, 
isaadakis).
This is, to our knowledge, the largest cohort of DR TB pediatric patients with HIV infection 
and TB treatment outcome described in the literature. Patients in the MDR TB hospitals 
were required to have culture confirmation before admission and initiation of treatment. As a 
result, this population of patients was more likely to have advanced disease (11). Almost 
every child included in this cohort had a positive sputum culture and more than half were 
HIV-infected.
Despite the severity of disease and high prevalence of co-infection, over half of our 
participants experienced favorable outcomes—treatment completion or cure. Individualized 
treatment regimens provided by experienced providers in a hospitalized setting has been 
shown to be successful in both adults and children with DR TB (28, 34). However, HIV-
infection was associated with higher mortality and survival analysis indicated that HIV-
infection had an impact on mortality of children with drug-resistant TB. Overall, 9.7% of 
our cohort had XDR TB, which is very similar to adults in South Africa (10.5% XDR TB 
among MDR TB cases) (35). These results indicated that the proportion of children with 
XDR TB or PreXDR TB was lower among those infected with HIV. This may be because 
pediatric patients with HIV-infection and pre-XDR or XDR TB did not live long enough to 
be admitted to treatment facilities that require culture confirmation, but a consistent 
association between HIV infection and XDR TB has not been documented. Primary drug 
resistance rather than acquired drug resistance is more common among children. Therefore, 
we think it unlikely that the pediatric patients acquired pre-XDR or XDR TB, but, rather, 
that these differences by HIV status could be related to differences in HIV infection and 
drug resistance transmission patterns in each region.
The occurrence of death in our cohort was relatively low when compared to adult patients 
with DR TB (36), but these findings are similar to those from a previous study of 84 children 
with MDR TB in South Africa that reported 11% mortality (36). This is likely, in part, 
related to prolonged hospitalization in facilities where providers are experienced in treating 
DR TB both with and without HIV infection. It is unclear why male pediatric patients were 
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more likely to have poor outcomes. Similar to a previous study, although HIV-infection was 
associated with shorter survival, malnutrition (based on weight-for-age Z-score) was the 
most predictive of death (36).
Limitations
This study has important limitations resulting from retrospective data collection limited to 
available medical records and charts. In general, medical charts at the MDR TB hospitals 
were comprehensive, though charting practices were inconsistent and variable across sites. 
Some data, such as contact history and history of antiretroviral therapy (ART), were often 
incomplete. When key data were unavailable in medical charts, they were obtained from 
laboratory and programmatic surveillance systems. Many of the HIV-infected patients did 
not have records of CD4 data or ART use. Therefore, we were unable to analyze the HIV-
infected group by severity of HIV-related disease or by HIV treatment status. In our time-to-
event analysis, about 25% of our participants had incomplete follow up data (lost to follow 
up, still on treatment, transferred or unknown). Finally, cause of death was not documented 
to a level of detail that could have enabled us to understand the influence of opportunistic 
infections (other than TB) on survival. Because we reviewed pediatric patients treated at 
MDR TB facilities, our findings are not generalizable to all children and adolescents with 
DR TB. More data from a variety of settings are needed to better understand true morbidity 
and mortality of all pediatric patients with DR TB.
Conclusion
The analysis of treatment outcomes among this large cohort of DR TB pediatric patients 
with HIV infection demonstrates that favorable outcomes are achievable. Although these 
patients were treated at MDR TB facilities by experienced clinicians, expertise and 
availability of medications to build effective regimens are improving. Based on history of 
previous treatment and contact to DR TB patients, there are opportunities for earlier 
diagnosis and treatment to improve outcomes for pediatric patients with DR TB. Renewed 
focus on early treatment with medications effective against resistant TB, life-saving ART, 
and nutritional rehabilitation will serve to improve outcomes among the most vulnerable of 
those affected by TB.
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Figure 1. 
Unadjusted Kaplan-Meier survival curves of poor treatment outcome during first 2-years of 
MDR TB treatment in three provinces, South Africa, 2005–2008.
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